Does Limosilactobacillus reuteri SD-LRE2-IT Disrupt Butyrate-Producing Bacteria?
Yes, certain strains of Limosilactobacillus reuteri can disrupt butyrate-producing bacteria in the gut, though this effect appears to be strain-specific and the SD-LRE2-IT strain has not been directly studied for this particular effect.
Evidence for Strain-Specific Disruption
The most compelling evidence comes from a 2024 study demonstrating that L. reuteri (unspecified strain) significantly depletes butyrate-producing gut microbiota, including Lachnospiraceae, Prevotellaceae, and Bifidobacterium 1. This study revealed several critical mechanisms:
- L. reuteri directly inhibited SCFA-producer growth and depleted butyrate in minimal microbiome culture models
- Genomic analysis showed enrichment in bacteriocins with known antimicrobial activity against SCFA-producing microbiota
- The depletion resulted in decreased bacterial metabolic pathways involved in butyrate production
- This effect was associated with worsened CNS autoimmunity in the EAE model
Contrasting Evidence with Other L. reuteri Strains
However, a 2025 study using L. reuteri ID-D01 showed the opposite effect, with significant increases in SCFA-producing bacteria (particularly Akkermansia spp.) and elevated production of acetate and butyrate 2. This stark contrast underscores that probiotic effects are highly strain-specific 3.
Critical Caveats
Strain Specificity is Paramount
The AGA guidelines explicitly state that "probiotic effects are strain-specific; each strain needs to be assessed individually" 3. The SD-LRE2-IT strain you're asking about has not been specifically studied in the available literature for its effects on butyrate-producing bacteria.
Diet-Dependent Effects
The 2024 study demonstrated that provision of excess dietary fiber abrogated the ability of L. reuteri to exacerbate disease, suggesting that the disruptive effects on butyrate producers can be mitigated through dietary intervention 1.
Clinical Context Matters
The disruption of butyrate-producing bacteria was observed in the context of autoimmune disease models. Whether this occurs in healthy individuals or other clinical contexts remains unclear.
Practical Implications
- Do not assume all L. reuteri strains behave identically regarding their effects on butyrate-producing bacteria
- If using L. reuteri probiotics in patients where butyrate production is therapeutically important (e.g., inflammatory bowel disease, metabolic syndrome), consider:
- Ensuring adequate dietary fiber intake (≥25-30g daily)
- Monitoring clinical response
- Considering alternative strains with documented SCFA-promoting effects
- The SD-LRE2-IT strain specifically requires dedicated research before conclusions can be drawn about its effects on the butyrate-producing microbiome